PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33087504-1	2020	Spinocerebellar ataxia type 3 (SCA3), caused by a CAG repeat expansion in the ataxin-3 gene (ATXN3), is characterized by neuronal polyglutamine (polyQ) ATXN3 protein aggregates.	polyglutamine	130-143	ataxin 3	Homo sapiens	0-29	
33087504-1	2020	Spinocerebellar ataxia type 3 (SCA3), caused by a CAG repeat expansion in the ataxin-3 gene (ATXN3), is characterized by neuronal polyglutamine (polyQ) ATXN3 protein aggregates.	polyglutamine	130-143	ataxin 3	Homo sapiens	78-86	
33087504-1	2020	Spinocerebellar ataxia type 3 (SCA3), caused by a CAG repeat expansion in the ataxin-3 gene (ATXN3), is characterized by neuronal polyglutamine (polyQ) ATXN3 protein aggregates.	polyglutamine	130-143	ataxin 3	Homo sapiens	93-98	
33087504-1	2020	Spinocerebellar ataxia type 3 (SCA3), caused by a CAG repeat expansion in the ataxin-3 gene (ATXN3), is characterized by neuronal polyglutamine (polyQ) ATXN3 protein aggregates.	polyglutamine	130-143	ataxin 3	Homo sapiens	152-157	
33087504-1	2020	Spinocerebellar ataxia type 3 (SCA3), caused by a CAG repeat expansion in the ataxin-3 gene (ATXN3), is characterized by neuronal polyglutamine (polyQ) ATXN3 protein aggregates.	polyglutamine	145-150	ataxin 3	Homo sapiens	0-29	
33087504-1	2020	Spinocerebellar ataxia type 3 (SCA3), caused by a CAG repeat expansion in the ataxin-3 gene (ATXN3), is characterized by neuronal polyglutamine (polyQ) ATXN3 protein aggregates.	polyglutamine	145-150	ataxin 3	Homo sapiens	78-86	
33087504-1	2020	Spinocerebellar ataxia type 3 (SCA3), caused by a CAG repeat expansion in the ataxin-3 gene (ATXN3), is characterized by neuronal polyglutamine (polyQ) ATXN3 protein aggregates.	polyglutamine	145-150	ataxin 3	Homo sapiens	93-98	
33087504-1	2020	Spinocerebellar ataxia type 3 (SCA3), caused by a CAG repeat expansion in the ataxin-3 gene (ATXN3), is characterized by neuronal polyglutamine (polyQ) ATXN3 protein aggregates.	polyglutamine	145-150	ataxin 3	Homo sapiens	152-157	
33087504-2	2020	Although there is no cure for SCA3, gene-silencing approaches to reduce toxic polyQ ATXN3 showed promise in preclinical models.	polyglutamine	78-83	ataxin 3	Homo sapiens	84-89	
33087504-5	2020	We show that polyQ ATXN3 serves as a marker of target engagement in human fibroblasts, which may bode well for its use in clinical trials.	polyglutamine	13-18	ataxin 3	Homo sapiens	19-24